Effect of Acalabrutinib in Combination with Bendamustine plus Rituximab on Survival Endpoints in Older Patients with Mantle Cell Lymphoma: Insights from the ECHO Trial
Mantle cell lymphoma (MCL) is a rare and often aggressive type of non-Hodgkin lymphoma that predominantly affects older adults and presents significant treatment challenges due to its clinical complexity and poor prognosis. Current frontline chemoimmunotherapy approaches frequently fail to provide l...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.22.163 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Mantle cell lymphoma (MCL) is a rare and often aggressive type of non-Hodgkin lymphoma that predominantly affects older adults and presents significant treatment challenges due to its clinical complexity and poor prognosis. Current frontline chemoimmunotherapy approaches frequently fail to provide long-term disease control. However, incorporating acalabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, into standard chemoimmunotherapy regimens shows promise in reducing disease progression and improving outcomes in older and unfit MCL patients.
The ECHO study evaluates the efficacy of acalabrutinib in combination with bendamustine plus rituximab (BR) in older MCL patients, aiming to provide a more effective and better-tolerated treatment option. Primary results demonstrate a significant improvement in progression-free survival and increased response rates with the acalabrutinib plus BR regimen compared with BR alone. While overall survival data are still maturing, early data show a modest trend favoring the acalabrutinib combination, indicating potential long-term benefits for this patient population.
Promising findings from the ECHO trial suggest that integrating acalabrutinib with standard therapy could set a new standard for frontline treatment in older/unfit MCL patients. This approach offers hope for improved outcomes and reduced toxicity, thereby addressing the unmet needs of this vulnerable population. Further research and exploration of this treatment paradigm hold promise for advancing the care and prognosis of patients with MCL.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Dr Veronika Ballova, Cantonal Hospital Baden, Baden, Switzerland
One anonymous peer reviewer
Received on September 02, 2024; accepted after peer review on November 25, 2024; published online on December 09, 2024. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |